Life Sciences Newsbrief — September 2009, Issue #11

New publication available called Putting IFRS in Motion: The Impact of International Financial Reporting Standards on the Canadian Pharmaceutical and Life Sciences Sector

IFRS will have a significant impact on businesses across all industries. Given the prevalence of strategic transactions among pharmaceuticals and life sciences companies, including acquisitions and alliances, companies need to understand how the new financial reporting requirements could impact these transactions. Several major international pharmaceuticals and life sciences companies are already reporting under IFRS, and the transition has had a significant impact on their financial reporting. This publication discusses the key accounting issues relevant to pharmaceutical and life sciences companies as they make their conversion to IFRS.

Weathering the Storm - Capital Funding Continues to Favor Massachusetts - July 2009

The Money Tree data shows that Massachusetts outperformed the nation in both year-over-year and quarter-over-quarter in 2008. However, life sciences funding fell over $200 million for the first time in more than two years. This trend report outlines the factors of the general funding by stage, deal and size. Pharmaceutical practitioners should leverage and customize these materials.